File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Helicobacter pylori infection - Current treatment practice

TitleHelicobacter pylori infection - Current treatment practice
Authors
Issue Date2001
PublisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eop
Citation
Expert Opinion On Pharmacotherapy, 2001, v. 2 n. 2, p. 253-266 How to Cite?
AbstractHelicobacter pylori infection, which is present in 30-60% of the population in developed countries and in more than 60% in developing countries, is established to be a major cause of gastritis, peptic ulcer disease and gastric cancer. Eradication therapy has been incorporated into clinical practice over the past 15 years. Treatment regimens include a 2 week bismuth-based triple therapy (a bismuth compound plus metronidazole, tetracycline or amoxycillin), a 1 week proton-pump inhibitor (PPI)-based triple therapy and a 1 week ranitidine bismuth citrate (RBC)-based triple therapy (a PPI or RBC plus any two of the three antibiotics, metronidazole, amoxycillin and clarithromycin). These regimens achieve eradication rates of > 80%. H. pylori resistance to metronidazole and clarithromycin decreases the clinical efficacy of most regimens, despite the high eradication rates for resistant strains achieved by the RBC-triple therapy in some recent trials. The dose of antibiotics (especially clarithromycin) and the duration of treatment may also influence the eradication rate. Doctors' beliefs impact on clinical practice and, thus, influence the clinical application of eradication therapy. Whereas peptic ulcer disease and primary gastric low-grade B-cell mucosa-associated lymphoid tissue lymphoma (MALToma) have become established as definite indications for eradication therapy, there remain controversies surrounding non-ulcer dyspepsia, gastro-oesophageal reflux disease, atrophic gastritis, intestinal metaplasia, use of non-steroidal anti-inflammatory drugs (NSAIDs) and H. pylori-related extradigestive diseases.
Persistent Identifierhttp://hdl.handle.net/10722/77075
ISSN
2015 Impact Factor: 3.543
2015 SCImago Journal Rankings: 0.884
References

 

DC FieldValueLanguage
dc.contributor.authorXia, HHXen_HK
dc.contributor.authorWong, BCYen_HK
dc.contributor.authorTalley, NJen_HK
dc.contributor.authorLam, SKen_HK
dc.date.accessioned2010-09-06T07:27:59Z-
dc.date.available2010-09-06T07:27:59Z-
dc.date.issued2001en_HK
dc.identifier.citationExpert Opinion On Pharmacotherapy, 2001, v. 2 n. 2, p. 253-266en_HK
dc.identifier.issn1465-6566en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77075-
dc.description.abstractHelicobacter pylori infection, which is present in 30-60% of the population in developed countries and in more than 60% in developing countries, is established to be a major cause of gastritis, peptic ulcer disease and gastric cancer. Eradication therapy has been incorporated into clinical practice over the past 15 years. Treatment regimens include a 2 week bismuth-based triple therapy (a bismuth compound plus metronidazole, tetracycline or amoxycillin), a 1 week proton-pump inhibitor (PPI)-based triple therapy and a 1 week ranitidine bismuth citrate (RBC)-based triple therapy (a PPI or RBC plus any two of the three antibiotics, metronidazole, amoxycillin and clarithromycin). These regimens achieve eradication rates of > 80%. H. pylori resistance to metronidazole and clarithromycin decreases the clinical efficacy of most regimens, despite the high eradication rates for resistant strains achieved by the RBC-triple therapy in some recent trials. The dose of antibiotics (especially clarithromycin) and the duration of treatment may also influence the eradication rate. Doctors' beliefs impact on clinical practice and, thus, influence the clinical application of eradication therapy. Whereas peptic ulcer disease and primary gastric low-grade B-cell mucosa-associated lymphoid tissue lymphoma (MALToma) have become established as definite indications for eradication therapy, there remain controversies surrounding non-ulcer dyspepsia, gastro-oesophageal reflux disease, atrophic gastritis, intestinal metaplasia, use of non-steroidal anti-inflammatory drugs (NSAIDs) and H. pylori-related extradigestive diseases.en_HK
dc.languageengen_HK
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eopen_HK
dc.relation.ispartofExpert Opinion on Pharmacotherapyen_HK
dc.subject.meshAgeden_HK
dc.subject.meshAnti-Bacterial Agents - administration & dosage - therapeutic useen_HK
dc.subject.meshAnti-Inflammatory Agents, Non-Steroidal - therapeutic useen_HK
dc.subject.meshAnti-Ulcer Agents - administration & dosage - therapeutic useen_HK
dc.subject.meshChilden_HK
dc.subject.meshClinical Trials as Topicen_HK
dc.subject.meshDrug Resistanceen_HK
dc.subject.meshDrug Therapy, Combinationen_HK
dc.subject.meshGastroesophageal Reflux - etiologyen_HK
dc.subject.meshHelicobacter Infections - complications - drug therapyen_HK
dc.subject.meshHelicobacter pylori - drug effectsen_HK
dc.subject.meshHumansen_HK
dc.subject.meshPeptic Ulcer - etiologyen_HK
dc.subject.meshStomach Neoplasms - etiology - prevention & controlen_HK
dc.titleHelicobacter pylori infection - Current treatment practiceen_HK
dc.typeArticleen_HK
dc.identifier.emailWong, BCY:bcywong@hku.hken_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1517/14656566.2.2.253en_HK
dc.identifier.pmid11336584en_HK
dc.identifier.scopuseid_2-s2.0-0035011951en_HK
dc.identifier.hkuros61714en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0035011951&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume2en_HK
dc.identifier.issue2en_HK
dc.identifier.spage253en_HK
dc.identifier.epage266en_HK
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridXia, HHX=8757161400en_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK
dc.identifier.scopusauthoridTalley, NJ=36045241200en_HK
dc.identifier.scopusauthoridLam, SK=7402279473en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats